The Changing Landscape of Non-Clinical Biomanufacturing (update for 2025) 🚀

Since stepping into the role of strategic advisor and coach after four years in cellular agriculture, I’ve had the chance to speak with founders, operators, and investors across the biomanufacturing space. One thing has stood out: early-stage funding in this sector isn’t what it used to be.

Many investors are hesitant to back pre-seed and seed-stage companies, especially in non-clinical biomanufacturing. The perception? The space is crowded, and they’re waiting to see how existing companies tackle three critical challenges: market entry, consumer adoption, and scalable production 📈. This is true of nearly all downstream products - cultivated meat, textiles, collagen based products etc.

But here’s the overlooked opportunity—new companies today have access to resources that simply didn’t exist a few years ago. Early pioneers had to build everything from scratch: cell lines, media, bioprocesses. What little infrastructure was available came from biopharma, carrying an eye-watering price tag 💰.

Fast forward to 2025, and the game has changed. A robust B2B ecosystem has emerged, offering specialized tools, technologies, and services. Instead of reinventing the wheel, new players can focus on assembling these components in the most effective way. Those who can integrate these building blocks strategically will have a real edge.

To illustrate this shift, I’ve mapped out an end-to-end value chain highlighting the B2B companies shaping the non-clinical biomanufacturing space. I shared a version of this map almost 12 months ago, and since then the number of companies has exploded (with a few that have pivoted and a few that haven't been successful).

This space is evolving rapidly, and I’m excited to see where it goes next. If you know of companies that should be included, drop them in the comments!

👉 If you want to check out these companies (or others) then check out the free databases on my website here.